PepGen Inc. PEPG
NASDAQ · United States · Health Technology
$2.28+0.07 (+3.17%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
BOSTON, August 06, 2026--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
BOSTON, August 06, 2026--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PepGen Inc. (NASDAQ:PEPG) is one of the best NASDAQ stocks under $5 to buy right now. On May 12, PepGen reported Q1 2026 financial results, recording a net loss of $17.8 million, or $0.26 per share, compared to a net loss of $30.2 million for Q1 2025. R&D expenses decreased to $13.0 million, down from […]
Brings more than 20 years of neurology, clinical development, and translational experience as AstronauTx prepares to advance its lead programmes into clinical developmentAstronauTx also appoints Deb Gouveia as Vice President, Clinical Operations and Development Strategy to further strengthen clinical development capabilities LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer's Disease and other neurological d
PepGen (NASDAQ:PEPG) reported top-line results from the lowest-dose cohort of its Phase II FREEDOM2 multiple ascending dose (MAD) study evaluating PGN-EDO-DM1 in myotonic dystrophy type 1 (DM1), highlighting what management characterized as encouraging safety, splicing, and functional trend data. F
The agency acted after reviewing mouse data submitted in 2024, making the timing of the new pause “confusing,” one analyst wrote.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.